Table 2.
Simulated geometric mean (CV%) steady-state exposures and joint PTA for ceftazidime and avibactam summarized by indication and by NP subgroup for patients with normal renal function (dose validation population PK model)
| Ceftazidime | Avibactam | Joint PTA, % | |||
|---|---|---|---|---|---|
| Cmax,ss (mg/L) | AUCss,0–24 (mg·h/L) | Cmax,ss (mg/L) | AUCss,0–24 (mg·h/L) | ||
| cIAI | 61.1 (44) | 683 (45) | 11.5 (83) | 121 (72) | 94.9 |
| cUTI | 73.0 (47) | 880 (49) | 11.2 (87) | 126 (82) | 95.2 |
| NP | 65.4 (53) | 805 (55) | 12.8 (94) | 147 (89) | 98.3 |
| NPv | 56.8 (51) | 723 (56) | 11.2 (82) | 131 (75) | 97.2 |
| VAP | 55.1 (59) | 719 (64) | 10.7 (85) | 129 (79) | 96.1 |
| Non-VAP | 75.7 (43) | 894 (48) | 14.7 (92) | 164 (93) | 100 |
AUCss,0–24 area under the concentration–time curve at steady state, Cmax,ss maximum plasma concentration at steady state, cIAI complicated intra-abdominal infection, CLCR creatinine clearance, cUTI complicated urinary tract infection, CV coefficient of variation, NP nosocomial pneumonia, NPv patients with a ventilator in the hospital room, which included patients with hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) who were ventilated on the day of PK sampling; PK pharmacokinetic, PTA probability of target attainment, q8h every 8 h
Data from Li et al. (2019) [32]. Simulations were conducted for 5000 patients with normal renal function (CLCR > 80 mL/min) in each indication, receiving ceftazidime–avibactam 2000/500 mg q8h as a 2-h intravenous infusion